{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000043","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.028913+00:00","generated_at":"2026-05-17T01:21:16.337445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review","bullets":["Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.","Net loss of $37.3M ($0.33 loss per share); adjusted EBITDA of $(3.0)M; gross margin 73% vs 77% YoY.","4,416 active patients globally as of Sept 30, 2025; Optune Gio prescriptions up 7% to 1,675.","PMA for TTFields in locally advanced pancreatic cancer accepted by FDA; PMA for brain metastases from NSCLC planned Q4 2025.","Cash and short-term investments $1,033.5M; Spain coverage for Optune Gio; Japan approval for Optune Lua with PD-1/L1."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000043","json":"https://secwatch.observer/filing/0001645113-25-000043.json","markdown":"https://secwatch.observer/filing/0001645113-25-000043.md","text":"https://secwatch.observer/filing/0001645113-25-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000043/0001645113-25-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000043/nvcr-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:21:16.337445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}